Journal
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
Volume 142, Issue 6, Pages 2760-2765Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jacs.9b12940
Keywords
-
Categories
Funding
- J1 Biotech Co., Ltd.
- National Key R&D Program of China [2018YFA0900400]
- National Natural Science Foundation of China [31670090, 31800032]
- Medical Science Advancement Program (Clinical Medicine) of Wuhan University [TFLC2018002]
Ask authors/readers for more resources
Herein, we report a short semisynthesis of the potent transient receptor potential canonical (TRPC) channel agonist englerin A (EA) and the related guaianes oxyphyllol and orientalol E. The guaia-6,10(14)-diene starting material was systematically engineered in Escherichia coli and Saccharomyces cerevisiae using the CRISPR/Cas9 system and was produced with high titers. The potentially scalable approach combines the advantages of synthetic biology and chemical synthesis providing an efficient and economical method for producing EA and analogues.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
